Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED)
Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline
Read MoreRESTON, VA —(BUSINESS WIRE)—Clarabridge, Inc., the leading provider of Customer Experience Management (CEM) solutions for the world’s top brands, experienced accelerated growth, demonstrated adaptability in a changing business environment and continued to develop its mission-critical platform.
Read MoreInvitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment.
Read MoreLearn what the 2020 Access Fund-Jeep Conservation Team has been doing to help steward and restore one of America's most iconic climbing areas, Lover's Leap in California.
Read MoreBroomfield, Colo. (June 30, 2020) – Datavail, an IT services company focused on database, analytics and application managed services, announced the promotion of COO Scott Frock to become CEO, and the addition of Kevin Walmsley to the executive team as CFO.
Read MoreBoulder Community Health has created a coronavirus screening and testing service for local businesses.
Named “Back-to-Business Health,” the service offers screening and testing to support employers’ efforts in protecting customers and to provide peace of mind for employees, according to a news release from BCH.
Read MoreBOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring.
Read MoreBOULDER, Colo., June 18, 2020 /PRNewswire/ – ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy.
Read MoreAUSTIN, Texas – May 12, 2020 – Zenoss Inc., the leader in intelligent application and service monitoring, today announced its company highlights for Q1 2020. Among many noteworthy accomplishments, Zenoss recorded key sales milestones in its Zenoss Cloud offering, the industry’s first full-stack monitoring plus AIOps platform.
Read More